The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Share News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Ark Therapeutics, Hambledon, Nighthawk ...

Tue, 08th Feb 2011 14:28

Drug developer Ark Therapeutics has sold the majority of its wound care business to Crawford Healthcare for up to £2.7m, comprising £0.77m upfront and up to £1.93m in milestone payments.The value of the gross assets being sold was put at £1,153,000 as at 30 June 2010. The losses on ordinary activities after tax attributable to the sold businesses was £428,000.Hambledon is increasing planned output from an underground mine currently being built at its Sekisovskoye operations in Kazakhstan.First ore is due to be extracted from underground in December and the extraction rate is now expected to grow to 850,000 tonnes per annum (tpa) over five years compared with the initial plan for 500,000tpa. Gold production from the underground mine alone is targeted to incrementally reach 65,000 ounces in 2014 and 110,000 ounces in 2016. Net production at oil company Nighthawk fell to 3,086 barrels of oil in the fourth quarter of 2010 from 4,092 barrels during the previous three months.It blamed the decline on more work-overs and recompletions in the period and said first quarter output will be broadly in line with December's number.Byotrol, the developer of anti microbial hygiene technologies, has extended its pact with own-label producer McBride to jointly develop and sell residual action liquid disinfectants in the European market. It is now expected that the first product will be launched in the first half of 2011. Byotrol and McBride intend to enter into full licence agreements, with UK product launches of Byotrol-based household care products expected in the third and fourth quarters of 2011. Home care operator Southern Cross Healthcare saw revenue dip in the final quarter of 2010 to £236.3m from £240.5m (restated) the year before, while the average occupancy rate on a like for like basis declined to 87.6% from 90.7% a year earlier.Adjusted earnings before interest, tax, depreciation and amortisation tumbled to £5.0m from a restated £14.4m in the corresponding period of 2009. Net debt during the quarter rose £14.1m to £21.4m. The group continues to engage with Landlords in pursuit of a restructuring of its lease terms and will provide a further update on this subject in due course.
More News
21 Dec 2009 12:00

London midday: Oil fired Footsie

Oil is fuelling the Footsie's rise today, with support from back-in-favour banks. Cairn Energy has secured a drill ship to get an early start on its exploration activities in Greenland. The oil company said drilling in Greenland will start a year ahead of schedule after it came to a deal with Hess

Read more
21 Dec 2009 08:59

US patent boosts Byotrol

Germ killing technology company Byotrol's share price received a boost after it said that it had its US patent application accepted. Byotrol, which applied for the patent in 2002, said the patent runs until 2022. Meanwhile, a Fortune 150 multinational company has paid Byotrol and its joint ventur

Read more
20 Nov 2009 17:28

Jorge Cosmen raises National Express stake

Shares in National Express raced ahead after deputy chairman Jorge Cosmen increased his family's influence over the company, spending more than £1.7m on shares in the train and bus operator. He bought just over 500,000 shares at 341p a time and now has about 29m, which is just shy of 20% of the com

Read more
17 Nov 2009 14:37

Byotrol's bumper interim revenues

Anti-microbial technology developer Byotrol reported strong revenue growth in the six months to September 2009 but this rate of growth will be difficult to maintain. Revenues jumped from £388,000 to £2m - more than double the level for the previous 12 months. Publicity about swine flu and other in

Read more
17 Sep 2009 08:39

Small caps round-up: Byotrol, ReNeuron, Accuma...

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations. Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in

Read more
16 Jun 2009 14:18

Kugler appointed chairman at Byotrol

Germ killing product developer Byotrol saw losses widen and sales slide slightly last year but said the current outlook is promising, as test results demonstrate the effectiveness of its hygiene technology. Revenue in the year to 31 March 2009 eased to £0.93m from £0.95m the year before, while loss

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.